NCT05958199 2025-06-27
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NextPoint Therapeutics, Inc.
Phase 1 Suspended
NextPoint Therapeutics, Inc.
Roger Williams Medical Center
Enzon Pharmaceuticals, Inc.
GlaxoSmithKline
Envita Medical Center, Inc.